LTFS
EIGR

Ladenburg Thalmann Financial Services’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-22
Closed -$7K – 5144
2017
Q3 		$7K Hold
22
– – ﹤0.01% 4274
2017
Q2 		$5K Hold
22
– – ﹤0.01% 4346
2017
Q1 		$7K Hold
22
– – ﹤0.01% 4185
2016
Q4 		$8K Hold
22
– – ﹤0.01% 4034
2016
Q3 		$9K Buy
+22
New +$11.2K ﹤0.01% 3898
2016
Q1 		– Sell
-1
Closed – – 4836
2015
Q4 		$0 Sell
1
-4
-80% -$2.26K ﹤0.01% 4813
2015
Q3 		$2K Hold
5
– – ﹤0.01% 4307
2015
Q2 		$3K Buy
+5
New +$13.8K ﹤0.01% 4260

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ladenburg Thalmann Financial Services's EIGR Position: Q4 2017 in Review

Ladenburg Thalmann Financial Services sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2017, closing a stake of 22 shares — an estimated $7K sold.

Ladenburg Thalmann Financial Services first reported a position in EIGR in Q2 2015 and held it in 8 quarters. The position peaked at $9K in Q3 2016. 40 funds tracked by Wall St. Rank hold EIGR as of Q4 2017.

  • Ladenburg Thalmann Financial Services reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 22 Eiger BioPharmaceuticals, Inc. shares in Q4 2017, an estimated $7K.
  • Ladenburg Thalmann Financial Services first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2015 and held it in 8 quarters.
  • Ladenburg Thalmann Financial Services's Eiger BioPharmaceuticals, Inc. position peaked at $9K in Q3 2016.
  • 40 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2017.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2017, filed 14 Feb 2018.